August 1, 2024 03:04 AM EDTUpdated 11:57 AM

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash

Amber Tong

Otsuka Pharmaceutical is paying at least $800 million to acquire Jnana Therapeutics, a Roche-partnered small molecule drug discovery outfit ready to put its first candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Up­dat­ed: Ot­su­ka buys out small mol­e­cule drug dis­cov­ery start­up Jnana and its rare dis­ease pill for $800M cash

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash